Edition:
United Kingdom

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

3.09USD
20 Jul 2018
Change (% chg)

$-0.06 (-1.90%)
Prev Close
$3.15
Open
$3.17
Day's High
$3.17
Day's Low
$3.07
Volume
8,985
Avg. Vol
62,656
52-wk High
$4.04
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Sophiris Bio Reports Q1 Loss Per Share $0.11
Monday, 14 May 2018 

May 14 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $0.11.SOPHIRIS BIO - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS ARE INITIATED.AT MARCH 31, 2018, CO HAD CASH, CASH EQUIVALENTS AND SECURITIES AVAILABLE-FOR-SALE OF $22.1 MILLION AND WORKING CAPITAL OF $19.2 MILLION.  Full Article

Sophiris Bio posts Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports third quarter financial results and key corporate highlights.Q3 loss per share $0.09.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Sophiris Bio Inc - qtrly ‍total operating expenses $3.3 million versus $3.7 million.  Full Article

Sophiris Bio Q2 earnings per share $0.02
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports second quarter financial results and key corporate highlights.Q2 earnings per share $0.02.Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Sophiris Bio- not planning on second Phase 3 trial in BPH, unless can secure development partner to fund new clinical trial or obtain other financing​.Sophiris Bio Inc- ‍expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018​.Sophiris Bio Inc- ‍expects to receive 24- week biopsy data for all patients from first dose of topsalysin in Q1 of 2018​.  Full Article

CVI Investments, Inc. reports 8.5 pct passive stake in Sophiris Bio
Friday, 26 Aug 2016 

: CVI Investments, Inc. reports 8.5 pct passive stake in Sophiris Bio as of August 23, 2016 - SEC Filing Source - http://bit.ly/2bSJTzU Further company coverage: [SPHS.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sabby Management, LLC reports 8.53 pct passive stake in Sophiris Bio
Thursday, 25 Aug 2016 

Sophiris Bio Inc : Sabby Management, LLC reports 8.53 pct passive stake in Sophiris Bio as of August 23, 2016 - SEC Filing Source - http://bit.ly/2bkUhn5 Further company coverage: [SPHS.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sophiris Bio currently evaluating options to further advance clinical development of Topsalysin
Monday, 22 Aug 2016 

Sophiris Bio Inc : Currently evaluating options to further advance clinical development of topsalysin - sec filing . "will require significant additional funding to advance topsalysin in clinical development" . Could use dilutive funding options like equity financing or "non-dilutive" funding options to fund future clinical development of topsalysin . Do not plan on pursuing new clinical trials, including a second phase 3 trial in bph, unless we obtain additional financing .Believe that earliest we could commercialize topsalysin for treatment of localized prostate cancer would be in late 2021 or into 2022.  Full Article

Sophiris Bio announces proposed public offering of common shares
Monday, 22 Aug 2016 

Sophiris Bio Inc :Sophiris Bio announces proposed public offering of common shares and warrants.  Full Article

Sophiris Bio Q2 loss per share $0.21
Tuesday, 9 Aug 2016 

Sophiris Bio Inc : Q2 loss per share $0.21 .Sophiris bio reports second quarter 2016 financial results and key business highlights.  Full Article

BRIEF-Sophiris Bio Q4 Loss Per Share $0.13

* SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS